申联生物(688098) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥81,851,831.18, representing a decrease of 8.08% compared to the same period last year[3] - Net profit attributable to shareholders was ¥15,867,632.60, down 33.69% year-on-year[3] - The company reported a net profit margin of approximately 22.0% for Q1 2023, compared to 28.0% in Q1 2022[16] - In Q1 2023, the company reported a net profit of CNY 15,867,632.60, a decrease of 33.5% compared to CNY 23,924,876.69 in Q1 2022[18] - Operating profit for Q1 2023 was CNY 19,162,338.23, down 33.2% from CNY 28,678,434.18 in the same period last year[20] - The company reported a total profit of CNY 19,111,308.51 in Q1 2023, a decrease of 33.1% from CNY 28,629,934.18 in Q1 2022[20] Research and Development - R&D expenses totaled ¥11,254,624.80, which is an increase of 10.54% compared to the previous year, accounting for 13.75% of revenue, up 2.32 percentage points[3] - The company is actively pursuing new technology and product development, with R&D expenses increasing significantly[6] - Research and development expenses increased to CNY 8,757,354.77, up 68.5% from CNY 5,196,621.48 in Q1 2022[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,600,170,365.42, a slight decrease of 0.31% from the end of the previous year[4] - Total assets as of March 31, 2023, were RMB 1,600,170,365.42, slightly down from RMB 1,605,083,700.71 at the end of 2022[13] - Total liabilities decreased to RMB 87,068,037.56 from RMB 108,209,232.05 at the end of 2022, a reduction of 19.5%[14] - Shareholders' equity increased to RMB 1,513,102,327.86 as of March 31, 2023, compared to RMB 1,496,874,468.66 at the end of 2022, an increase of 1.1%[14] Cash Flow - Cash and cash equivalents as of March 31, 2023, were RMB 45,884,713.20, down from RMB 52,742,562.11 at the end of 2022, representing a decrease of 13.4%[12] - Cash flow from operating activities showed a net outflow of CNY 32,986,013.65, an improvement from a net outflow of CNY 42,272,933.50 in Q1 2022[20] - Total cash and cash equivalents at the end of Q1 2023 were CNY 45,727,802.46, down from CNY 53,005,125.45 at the end of Q1 2022[21] - The company generated CNY 33,979,285.31 in cash from sales in Q1 2023, a significant increase from CNY 21,017,968.10 in Q1 2022, representing a growth of 61.2%[20] - Investment activities generated a net cash inflow of CNY 26,338,281.46 in Q1 2023, compared to CNY 51,106,906.26 in Q1 2022[21] Shareholder Information - The top shareholder, Yang Yufang, holds 21.93% of the shares, totaling 90,063,197 shares[8] - The basic earnings per share were ¥0.04, reflecting a decrease of 33.33%[3] - The basic earnings per share for Q1 2023 was CNY 0.04, down from CNY 0.06 in Q1 2022[18] Market and Sales - The company experienced a decline in sales due to delayed government procurement for foot-and-mouth disease vaccines, impacting revenue[6] - The company plans to focus on expanding its market presence and developing new products in the upcoming quarters[10]